Longeveron Return on Equity

Longeveron (LGVN) currently reports a ROE of -225.67%. That is below the Healthcare sector average of 21.18%. Use the charts on this page to explore Longeveron's ROE history and peer comparisons.

Longeveron's ROE of -225.67% is lower than the Healthcare sector average of 21.18%. That is roughly 1165.4% below the sector mean. A reading lower peers can reflect different growth expectations, capital structure, or profitability — so it is worth checking the peer comparison chart before drawing conclusions.

There is no universal 'good' ROE, but Longeveron's current -225.67% should be judged against Healthcare norms (sector average: 21.18%) and against LGVN's own history. Strong, stable readings often indicate durable competitive advantage; volatile or declining ones deserve a closer look at margins and capital efficiency.

Start with the current ROE of -225.67%, then check the historical chart for trend and the peer comparison chart for relative positioning. The Healthcare average is 21.18%. From there, open related valuation or income-statement pages for Longeveron, and consider following LGVN for alerts when major investors trade the stock.

Longeveron is classified in the Healthcare sector. On ROE, it currently shows -225.67% versus a sector average near 21.18%. Sector peers often share similar capital intensity and growth regimes, so relative rankings inside Healthcare are usually more informative than comparing LGVN with unrelated industries.